Last Updated: July 27, 2026

Details for Patent: 11,896,759


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,896,759
Title:Inhalers and related methods
Abstract:An inhaler (10) has a main body for accommodating a medicament reservoir (84), a canister fire system for moving a canister (50) to release a dose in response to air flow, a cap housing (12) for enclosing the canister fire system and canister within an interior chamber defined by the main body (14) and a cap housing, wherein a lock system (250) is provided for locking the cap housing on the main body.
Inventor(s):Daniel Buck, Paul Prendergast, Declan Walsh
Assignee: Norton Waterford Ltd
Application Number:US17/949,483
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,896,759
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;
Patent landscape, scope, and claims:

US Drug Patent 11,896,759: Scope, Claim Architecture, and US Patent Landscape

US 11,896,759 covers an inhaler architecture that combines (i) a pressurized canister with a liquid-filled reservoir feeding a metering chamber via a valve stem communication path that is directionally switchable for liquid-in and gas-out behavior, and (ii) a cap-to-body locking system that uses helical threads with non-overlapping axial thread segments and a “first lock member interposed between the thread segments” to produce a rotational snap lock with controlled release torque (quantified in multiple dependent claims). The same claim set then layers dose control, reset prevention of metering chamber exposure to atmosphere, canister-firing mechanics, and multiple device form factors (oral and nasal; breath-actuated; metered dose; dose counter mechanics).

This is a “core inhaler + lock architecture” claim set with a long tail of dependent claims that broaden across functional inhalation systems and user-proof dosing behavior.


1. What is the claimed invention in one view?

Core independent claim (Claim 1): structural + functional lock and valve feeding

Claim 1 requires all of the following in one device:

  1. Inhaler body and cap

    • Main body
    • Cap housing defining an interior chamber
  2. Pressurized canister in the interior chamber

    • Canister enclosed within the interior chamber
    • Interior reservoir containing “pressurised inhalable substances including fluid”
  3. Metering valve with defined communication path

    • Metering valve includes:
      • Metering chamber
      • Valve stem defining a communication path between:
      • Transfer space inside valve stem
      • Interior reservoir
    • The communication path includes a first opening permitting flow between transfer space and interior reservoir
    • Orientation requirement: interior reservoir is arranged for orientation above the metering chamber such that
      • gas in the metering chamber is replaced with liquid from the interior reservoir
  4. Lock system: helical threads + snap lock + controlled axial thread geometry

    • Lock system locks cap housing on main body
    • Lock system includes:
      • Helical threads having non-overlapping and distinct thread segments
      • Rotational attachment of cap housing to main body
      • A first lock member cooperates with a second lock member to achieve snap lock when the cap housing is rotationally attached in a locked position
    • Thread geometry:
      • Thread segments radially disposed about a central axis
      • Thread segments are non-overlapping with respect to each other along the central axis
      • First lock member is interposed between the thread segments
  5. Lock resistance language in dependent claims

    • Dependent claims recite resistance to relative longitudinal movement and resistance to rotation (Claim 2)
    • Additional torque windows appear in Claims 4-6 and 43-44

Net effect: Claim 1 ties together a specific internal fluid-gas exchange feeding behavior (liquid replaces gas in the metering chamber by gravity/positioning and valve path openings) with a specific cap retention mechanism characterized by non-overlapping axial thread segments plus interposed lock member geometry producing snap lock.


2. How broad is Claim 1 versus the dependent claims?

Claim 1 breadth

Claim 1 is broad at the level of:

  • “Inhaler” (no limitation to specific administration route in Claim 1)
  • “Inhalable substances including fluid” and “pressurised” (generic formulation coverage)
  • Valve stem communication path defined by openings and orientation above metering chamber (functional plus structural)
  • Lock geometry defined by:
    • helical threads with non-overlapping distinct thread segments
    • snap lock with interposed first lock member

It is narrower at:

  • Specific internal arrangement (reservoir above metering chamber)
  • Specific communication path concept (transfer space, first opening)
  • Specific lock geometry (thread segment non-overlap along central axis; interposed lock member)

Dependent claims expand device permutations

Claims 2-44 expand scope through parameterization (torque windows) and functional features (reverse flow behavior; elongated openings; venting to atmosphere; canister fire system; reset actuator and preventer; dose counter and barrier; breath-actuated/oral/nasal; equilibrium of springs).

A. Lock system definition tightening (Claims 2-6, 43-44)

  • Claim 2: resists relative longitudinal movement and rotation
  • Claim 3: protrusion in helical thread region lockable in recess on mating helical thread region
  • Claim 4: plastics main body and cap housing; release torque > 1 Nm
  • Claim 5: release torque < 4 Nm
  • Claim 6: release torque between 2 and 5 Nm
  • Claim 43: release torque < 4 Nm (redundant reinforcement)
  • Claim 44: release torque between 2.5 and 3 Nm (tight window)

Practical consequence: The claim set is engineered so competitors cannot easily “design around” torque characteristics without either changing the lock geometry or moving outside the torque band.

B. Valve stem communication path refinements (Claims 7-11)

  • Claim 7: communication path permits liquid flow under pressure to metering chamber and gas in reverse direction from metering chamber into interior reservoir
  • Claim 8-10: first opening elongated; second opening (or multiple) into communication path; second opening diametrically opposed to first opening
  • Claim 11: valve stem has at least one opening into interior reservoir with an axially oriented portion facing directly axially; flow of fluid into communication path along axial direction along valve stem

Practical consequence: These claims target specific porting and reverse-flow management that is central to the claimed “replace gas with liquid” behavior.

C. Metering chamber venting (Claim 12)

  • Metering chamber exit port venting to atmosphere via stem block and/or nozzle

D. “Canister fire system” mechanics and reset control (Claims 13-20)

  • Claim 13: canister fire system enclosed in interior chamber; eject inhalable substances in response to air flow by:
    • closing communication between metering chamber and interior reservoir
    • opening communication between metering chamber and atmosphere
  • Claims 14-17: drive drives canister relative to valve stem; includes drive spring
  • Claim 16: adapted to depress valve stem into canister to eject substances and hold valve stem depressed with metering chamber communicating with atmosphere
  • Claim 17: reset actuator extends valve stem relative to canister to close atmosphere-meting chamber communication and reopen metering chamber to interior reservoir
  • Claims 18-19: reset actuator comprises mouthpiece cap; preventer stops further inhalation until mouthpiece cap closed to extend valve stem
  • Claim 20: preventer includes warning signaller (audible/visual/dose counter/warning notice)

E. Actuation, formulation, and dose counter (Claims 21-28)

  • Claim 21-22: actuator system for operating drive; actuable by air flow
  • Claim 23: inhalable substances comprise at least one propellant
  • Claim 24-27: dose counter counts doses per inhalation; tape dose indicia and/or actuator pin; barrier separates dose counter chamber from inner space for containing canister
  • Claim 28: nasal inhaler barrier comprises stepped barrier with vertical and horizontal surfaces; dose counter coupled to vertical and/or horizontal surface

F. Device type: breath actuated, MDI, oral, nasal (Claims 29-32)

  • Claim 29: breath actuated inhaler
  • Claim 30: metered dose inhaler
  • Claim 31: oral inhaler
  • Claim 32: nasal inhaler

G. Metering chamber exposure prevention and dose overfill performance (Claims 33-36)

  • Claim 33: reset actuator prevents exposure of metering chamber to atmosphere; device provides 75 to 125% of labelled claim for a dose following exposure to atmosphere lasting more than one minute
  • Claim 34: more than two minutes
  • Claim 35: time window escalates to one hour, more than one hour, 24 hours, more than 24 hours (exposure tolerance)
  • Claim 36: reset actuator is mouthpiece cap that, when closed, prevents metering chamber exposure to atmosphere

Practical consequence: These claims impose measurable performance tolerance after metering chamber exposure. They are among the most “non-standard” elements relative to typical MDI lock claims and can support enforcement if performance testing is repeatable.

H. Spring equilibrium and suction force (Claims 37-39)

  • Claim 37: metering valve spring and opposing canister spring; arrangement provides force equilibrium in at least one ready-to-fire configuration
  • Claim 38-39: at least one suction force; suction force operates against canister spring

I. Nasal inhaler-specific structure: nosepiece cap, yoke, cam (Claims 40-42)

  • Claim 40: nasal inhaler with nosepiece cap coupled to main body; nosepiece cap moves closed to open; yoke coupled to main body and canister; yoke moves as nosepiece cap moves; canister moves as yoke moves
  • Claim 41: nosepiece cap includes cam; yoke includes leg engageable with cam such that rotation of nosepiece cap causes yoke movement
  • Claim 42: canister moves from storage position to dispensing position as yoke moves

3. Claim-by-claim scope map (what each adds)

Lock system scope

Claims Lock/attachment limitation added
1 Helical threads with non-overlapping distinct thread segments; snap lock by first lock member + second lock member; first lock member interposed between thread segments; cap locked position defined by rotational attachment
2 Resists longitudinal movement and resists rotation relative to main body
3 Protrusion/recess in regions of helical thread elements (one on body, one on cap)
4 Plastics main body and cap; release torque > 1 Nm
5 Release torque < 4 Nm
6 Release torque 2 to 5 Nm
43 Release torque < 4 Nm
44 Release torque 2.5 to 3 Nm

Valve and flow path scope

Claims Flow path/port limitation added
1 Metering valve stem communication path includes first opening; reservoir oriented above metering chamber to replace gas with liquid
7 Reverse-direction gas flow from metering chamber to interior reservoir; liquid under pressure flows to metering chamber
8-10 First opening elongated; optional second openings; second opening diametrically opposed to first
11 Axially oriented portion of valve stem opening; axial flow into communication path

Metering chamber handling and venting

Claims Metering chamber feature added
12 Metering chamber exit port vents to atmosphere via stem block/nozzle
33-36 Reset actuator prevents metering chamber exposure to atmosphere; dose accuracy tolerance after exposure durations (minute to 24+ hours)

Dose delivery mechanics and reset

Claims Delivery/actuation feature added
13 Canister fire system; air flow triggers closure/opening between reservoir and atmosphere via metering chamber communications
14-15 Drive moves canister relative to valve stem; drive includes drive spring
16 Depress valve stem into canister to eject; hold valve stem depressed while metering chamber communicates with atmosphere
17 Reset actuator extends valve stem to close atmosphere communication and reopen to interior reservoir
18-20 Mouthpiece cap used as reset actuator; preventer blocks further inhalation until cap closed; warning signaller/dose counter/audible/visual notice

Device form factor and counters

Claims Coverage added
21-22 Actuator system operates drive; air-flow actuable
23 Includes propellant
24-28 Dose counter; tape indicia and/or actuator pin; barrier separating dose counter chamber from canister chamber; nasal stepped barrier with surfaces coupled to dose counter
29-32 Breath actuated; metered dose; oral and nasal
40-42 Nasal mechanical linkage: nosepiece cap, yoke, cam/leg, canister storage-to-dispensing motion

4. How does this sit in the broader US patent landscape?

Landscape character: “lock interface + metering valve liquid-gas exchange + reset prevention”

Within US inhaler patents, three clusters typically dominate:

  1. MDI / breath-actuated inhalers with metering chambers and gas-liquid management
  2. Reset mechanisms and user-proof dose sequencing that prevent mis-dosing
  3. Cap-to-body mechanical locking, retention, and tamper resistance (thread geometry and snap locks)

US 11,896,759 claims a combination that is uncommon in a single set: it merges a liquid replacement of metering chamber gas via an oriented pressurized reservoir and valve stem openings, with a cap lock system defined by non-overlapping helical thread segments and interposed lock member snap-lock geometry. The later claims further expand into dose counter architecture and reset performance after metering chamber exposure.

Enforcement posture implied by claim design

  • High certainty infringement zones
    • Cap lock with non-overlapping helical thread segments, snap lock between first and second members, and interposed first lock member geometry
    • Torque-limited plastics lock (release torque bands)
    • Reset actuator that prevents metering chamber exposure to atmosphere and sustains dose accuracy after specified exposure times
  • Medium certainty zones
    • Port geometry: elongated opening, diametrically opposed opening, axially oriented valve stem openings
    • Canister fire system sequence tied to air flow by changing communications between metering chamber and reservoir/atmosphere
  • More conditional zones
    • Specific nasal mechanical linkage (cam and yoke leg; yoke motion moving canister)
    • Dose counter mechanics (tape indicia, actuator pin, barrier stepped structure)

Potential “design around” targets

  • Replace the snap-lock thread geometry with an alternative retention mechanism that does not use non-overlapping helical thread segments with an interposed lock member between those segments.
  • Achieve retention outside the claimed release torque windows.
  • Change the valve stem communication path such that gas-liquid exchange in the metering chamber is not achieved via the claimed “reservoir above metering chamber” arrangement and the claimed communication path first opening.
  • Eliminate the “prevent exposure of metering chamber to atmosphere” reset behavior and/or fail the post-exposure dose accuracy tolerance.

5. Freedom-to-operate (FTO) focus: what to search and map in competing products

Even without knowing the full prosecution history, the claim language identifies specific technical features that FTO teams can map to competitor designs:

Lock system mapping

  • Helical threads on cap and body with non-overlapping distinct thread segments along the central axis
  • First lock member interposed between the thread segments
  • Snap lock engagement producing locked position after rotational attachment
  • Plastics cap/body with release torque >1 Nm and <4 Nm and/or 2 to 5 Nm bands
  • Particular protrusion/recess implementation on helical thread regions

Metering valve mapping

  • Metering chamber gas replaced by liquid due to:
    • reservoir oriented above metering chamber
    • valve stem communication path with first opening between transfer space and interior reservoir
  • Bidirectionality:
    • liquid flow under pressure to metering chamber
    • reverse gas flow to interior reservoir

Reset and metering chamber exposure

  • Reset actuator as mouthpiece cap
  • Preventer stopping further inhalation until cap closed
  • Preventing metering chamber exposure to atmosphere and dose accuracy tolerance after:
    • 1 minute

    • 2 minutes

    • 1 hour, >1 hour, 24 hours, >24 hours

Delivery sequence

  • Canister fire system enclosed in interior chamber
  • Air-flow triggering closure/opening between:
    • metering chamber and interior reservoir
    • metering chamber and atmosphere

Dose counter and nasal linkage

  • Dose counter counted per inhalation
  • Barrier separating dose counter chamber from canister chamber
  • Nasal stepped barrier and dose counter coupling locations
  • Nosepiece cap cam + yoke leg kinematics moving canister from storage to dispensing

Key Takeaways

  • US 11,896,759 is organized around Claim 1’s combination of (1) valve-driven liquid-gas exchange in a metering chamber using a reservoir oriented above the metering chamber and a valve stem communication path with specific openings, plus (2) a cap locking system defined by non-overlapping helical thread segments, snap lock via cooperating members, and a first lock member interposed between thread segments.
  • Dependent claims concentrate enforcement leverage into three measurable zones: release torque bands for the snap-thread lock; dose accuracy tolerance after metering chamber exposure to atmosphere; and detailed valve stem opening/port geometries and bidirectional flow behavior.
  • The landscape fit is combination coverage: many US inhaler patents cover either dose reset/user-proofing, or cap locking, or metering/valve fluid handling, but this claim set ties them together and then extends into oral and nasal mechanical embodiments and dose counter architectures.

FAQs

  1. What is the single most important independent claim element set?
    Claim 1 requires both the liquid-gas metering valve behavior (reservoir above metering chamber with communication path openings) and the specific snap-lock cap system (non-overlapping helical thread segments with an interposed lock member).

  2. Which claims most constrain competitors on the cap lock design?
    Claims 2-6 plus 43-44: they add resistance to longitudinal movement and rotation and tighten release torque ranges, including plastics lock with torque >1 Nm and <4 Nm and specific 2 to 5 Nm and 2.5 to 3 Nm bands.

  3. Which claims impose performance-based compliance requirements?
    Claims 33-36: they specify dose delivery accuracy relative to labeled claim (75 to 125%) after metering chamber exposure durations ranging from >1 minute to 24+ hours, with a mouthpiece cap preventing exposure.

  4. Does the patent cover both valve flow directions?
    Yes. Claim 7 explicitly includes liquid flow under pressure to the metering chamber and reverse-direction gas flow from the metering chamber into the interior reservoir.

  5. Where does nasal-specific structure appear?
    Claims 28 and 40-42: stepped barrier/dose counter coupling and a nasal mechanical linkage using a nosepiece cap with cam and a yoke that moves to reposition the canister from storage to dispensing.


References

  1. User-provided claim text for US Drug Patent 11,896,759 (claims 1-44).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,896,759

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Norton Waterford QVAR REDIHALER beclomethasone dipropionate AEROSOL, METERED;INHALATION 207921-002 Aug 3, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,896,759

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 3052339 ⤷  Start Trial
European Patent Office 3582837 ⤷  Start Trial
European Patent Office 4066874 ⤷  Start Trial
Spain 2909034 ⤷  Start Trial
Spain 2981585 ⤷  Start Trial
United Kingdom 201702408 ⤷  Start Trial
Portugal 3582837 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.